The construction of Changchun Overseas Pharmaceutical Production Base invested with RMB1.2 billion was started in Changchun Hi-tech Industry Development Zone.  

The project is invested by Changchun Overseas Pharmaceutical Group Co., Ltd., whose predecessor Jinlai Pharmaceuticals was founded in 1988, a large group integrating science, industry and trade. In 1991, it established a factory in Changchun Hi-tech Industry Development Zone, the first of its kind settled in the Biological Pharmaceutical Park engaged in producing western medicines, Chinese patent medicines and biological preparations. The company covers an area of 28,000 square meters and a building area of 44,000 square meters. It is one of the first national GMP certified enterprises. The company has more than 1,100 drug approval numbers and such famous independent brands “exclamation mark”, one of the top ten cold medicines in China and “overseas touteng tablets”, a kind of headache medicine ranking atop similar ones at home. With equal importance attached to scientific research and production, its scientific research and technical personnel account for more than 60% of the total number of employees. Last year, the output value totaled RMB283 million and the amount of profits and taxes amounted to RMB32.56 million. 

The project of Changchun Overseas Pharmaceutical Production Base invested and constructed this time covers an area of 50,400 square meters and a building area of 150,000 square meters, mainly for the development of health industry, the construction of health food and pilot test base, medicine storage and logistics, headquarters building, R&D base, and the production of more than 100 kinds of medicines including “exclamation mark” and ibuprofen. Once going operational, the project will bring about an annual output value of RMB3 billion and a total amounts of profits and taxes of RMB300 million.